Similarly, we deduced that the degradation of FLT3 mutation oncoprotein involved with bortezomib may also eradicate FLT3-mutated leukemia cells, and then it will achieve better therapeutic effects when combined with other drugs, such as FLT3 inhibitor or chemotherapy agents. This evidence concerns the gene FLT3 and leukemia.